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Summary
Deficiency of the GM2 activator protein, encoded by
GM2A, results in the rare AB-variant form of GM2 gan-
gliosidosis. Four mutations have been identified, but the
human gene structure has been only partially charac-
terized. We report a new patient from a Laotian deme
whose cells are deficient in both GM2-activator mRNA
and protein. However, reverse transcription (RT)-PCR
detected some normal-sized cDNA and a smaller cDNA
species, which was not seen in the RT-PCR products
from normal controls. Sequencing revealed that, al-
though the patient’s normal-sized cDNA contained a
single nonsense mutation in exon 2, his smaller cDNA
was the result of an in-frame deletion of exon 2. Long
PCR was used to amplify introns 1 and 2 from patient
and normal genomic DNA, and no differences in size,
in 5′ and 3′ end sequences, or in restriction-mapping
patterns were observed. From these data we developed
a set of four PCR primers that can be used to identify
GM2Amutations. We use this procedure to demonstrate
that the patient is likely homozygous for the nonsense
mutation. Other reports have associated nonsense mu-
tations with dramatically reduced levels of mRNA and
with an increased level of skipping of the exon contain-
ing the mutation, thus reestablishing an open reading
frame. However, a recent article has concluded that, in
some cases, the latter observation is caused by an artifact
of RT-PCR. In support of this conclusion, we demon-
strate that, if the competing, normal-sized cDNA is re-
moved from the initial RT-PCR products, from both
patient and normal cells, by an exon 2–specific restric-
tion digest; a second round of PCR produces similar
amounts of exon 2–deleted cDNA.
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Introduction
The correct synthesis and interaction of three gene prod-
ucts are needed to hydrolyze GM2 ganglioside (GM2).
Two of these are the a and b subunits of the lysosomal
glycosidase b-hexosaminidase A (Hex A; E.C.3.2.1.52),
which irreversibly dimerize in the endoplasmic reticu-
lum. The third is the Hex A substrate (GM2)–specific
cofactor, the GM2 activator protein (Activator), which
forms a complex with GM2 and then reversibly interacts
with Hex A in the lysosome (Gravel et al. 1995; Ma-
huran 1998; Mahuran, in press). These three proteins
are encoded by the HEXA, HEXB, and GM2A genes,
respectively. Although 87 and 23 mutations in
HEXA and HEXB have been associated with various
forms of Tay-Sachs disease and Sandhoff disease, re-
spectively, only four mutations in GM2A have been de-
scribed, and all are likely to occur in the homozygous
form in four patients with the AB-variant form of acute
GM2 gangliosidosis (MIM 272750; reviewed by Gravel
et al. 1995; Mahuran, in press). Although the size, place-
ment, and partial nucleotide sequence at each end of the
introns in human HEXA and HEXB have been deter-
mined (Proia and Soravia 1987; Neote et al. 1988; Proia
1988), those comprising GM2A have been incompletely
characterized (Klima et al. 1991).
It is known that, in vivo, the GM2A mRNA is rare
and requires the use of poly A RNA to be detected by
northern blotting techniques, which have estimated its
length to be ∼2.5 kb. The Activator’s coding region com-
prises only 582 nucleotides, with most of the remainder
forming a long 3′ untranslated end sequence (Klima et
al. 1991; Xie et al. 1991; Nagarajan et al. 1992). GM2A
has been mapped to chromosome 5q 31.3-33.1 (Heng
et al. 1993; Swallow et al. 1993), and there is also a
nonfunctional processed GM2A pseudogene on chro-
mosome 3 (Xie et al. 1992a; Swallow et al. 1993).
GM2A is a small gene, 16 kb in length. Exons 2–4
have been identified in genomic clones, with the exis-
tence of exon 1 being extrapolated to account for the
remaining 81 bp of 5′ coding sequence found in cloned
cDNA. Among the three introns, only the 0.38-kb intron
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3 has been fully sequenced. The 5′ and 3′ end sequences
of intron 1 and 2 remain incomplete (Klima et al. 1991).
In this article, we identify a fifth mutation in GM2A,
a nonsense mutation in exon 2 (Glu54STOP). As in the
other four documented AB-variant cases, the mutation
is likely present in the homozygous form (the possible
presence of a second large GM2A deletion allele could
not be completely ruled out, in any of these cases), and
the patient exhibits the acute GM2 gangliosidosis phe-
notype, similar to acute Tay-Sachs and Sandhoff disease
(reviewed by Gravel et al. 1995; Mahuran, in press). In
the course of characterizing the biochemical effects of
this nonsense mutation on mRNA splicing and stability,
we determined the size, partial-restriction map, and 5′
and 3′ end sequences of GM2A’s three introns. We also
designed four pairs of primers that can be used with
common PCR conditions for the amplification of the
coding sequence plus each of the intron/exon junctions
of GM2A. These four PCR reactions, done simulta-
neously, make it possible for other investigators to ef-
ficiently screen GM2A for new mutations.
Finally, in the context of our novel GM2A nonsense
mutation, we examine the controversy (reviewed by Ma-
quat 1996) surrounding the hypothesis that nonsense
mutations promote the skipping of the exon in which
they are contained, to reestablish the reading frame
(Dietz et al. 1993; Mazoyer et al. 1998). This hypothesis
would require the presence in the nucleus of a mecha-
nism for reading the frame prior to the splicing out of
introns (reviewed by Dietz and Kendzior 1994).
Patient and Methods
Case Report
The patient, a child of Laotian Hmong ancestry (i.e.,
from a geographically isolated, small Laotian hill tribe),
was first examined at age 2.5 years for evaluation of his
neurodegenerative course. He was the product of a term
pregnancy complicated only by decreased fetal activity
late in gestation. Two older siblings and one younger
sibling were clinically normal. Careful evaluation of the
family pedigree revealed no consanguinity. The child was
thought to be normal until age ∼5 mo, when he was
noted to have delayed motor milestones and increasing
weakness. At age 9 mo, magnetic resonance imaging
showed increased signal density in the periventricular
white matter and altered signal density in the basal gan-
glia. Ophthalmologic evaluation showed bilateral mac-
ular cherry-red spots. Lysosomal enzyme studies showed
normal enzyme activity in lymphocytes for Hex A, ar-
ylsulfatase A, a-L iduronidase, sphingomyelinase, gal-
actocerebrosidase, and mannosidase. Additional labo-
ratory evaluation included normal very-long–chain fatty
acid and phytanic acid levels, normal quantitative test
results on amino and organic acids, normal lactate and
pyruvate levels, and normal findings of mitochondrial
DNA studies.
At the time of evaluation, the patient was experiencing
approximately three major motor seizures and hundreds
of myoclonic jerks per day. Hyperacusis was extreme,
with an exaggerated startle response. Frequent suction-
ing was required for pooling of secretions in the oro-
pharynx, and sucking and swallowing were impaired.
He was able to indicate hunger by crying and responded
minimally to the family.
Physical examination revealed a nondysmorphic, pro-
foundly hypotonic child, who was unresponsive to his
environment. He had numerous myoclonic seizures and
distinct hyperacusis. Growth parameters included a head
circumference of 50 cm (50th percentile), height of 35.5
cm (25th–50th percentile), and weight of 10.2 kg (3d
percentile). There was a bell-shaped thorax and pectus
excavatum. Abdominal muscles were weak, with dias-
tasis recti. Tone was diffusely and severely decreased.
Deep-tendon reflexes were brisk, with bilateral ankle clo-
nus. There was profound head lag and severe generalized
hypotonia. Mild contractures were seen at the elbows,
knees, and ankles. Roving eye movements with no-gaze
palsy were noted. There was minimal response to painful
stimuli.
Despite the normal Hex A levels in lymphocytes, the
clinical evaluation strongly suggested Tay-Sachs disease.
A lumbar puncture was done for ganglioside profile,
which revealed a highly elevated total ganglioside con-
tent (performed by Dr. David Wenger at Jefferson Med-
ical College, Philadelphia). Skin biopsy was done for
fibroblast DNA analysis.
The patient was last examined at age 2 years 8 mo,
at which time he had increasing respiratory distress and
severely decreased muscle mass. He was subsequently
admitted for pneumonia. The family moved out of state
after the child was discharged from the hospital. We
assume that the patient expired but are unable to confirm
his age at death.
Cell Lines and Leukocyte Sample
Two normal fibroblast cell lines, referred to as N1 and
N2, were obtained from the tissue-culture facility at the
Hospital for Sick Children. The patient’s cultured fibro-
blast cells were obtained from Valley Children’s Hos-
pital. These fibroblast cell lines were grown in a-minimal
essential media (aMEM; Flow Laboratories) supple-
mented with 10% (v/v) fetal-calf serum, 100 mg strep-
tomycin/ml, and 100 mg penicillin/ml.
Western Blot Analysis
The confluent fibroblast cells from N1 and N2 and
the cells from the Laotian patient were harvested with
NaH2PO4 lysis buffer (10 mM NaH2PO4 with 5% glyc-
erol) and subjected to five rounds of freeze thawing. The
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lysate was extracted with an equal volume of CCl4, and
the total protein was determined (Lowry et al. 1951).
Fifty micrograms and 100 mg of total lysate protein, from
normal or from patient cells, were mixed separately with
equal volumes of loading buffer (containing 20 mM
DTT and 4% SDS), and were then boiled for 5 min.
Western blotting was done as described elsewhere (Xie
et al. 1992b).
Poly A RNA Isolation and Northern Blot Analysis
Since the activator mRNA is rare (Xie et al. 1991),
poly A RNA must be used for northern blot analysis.
Northern blot analysis of 4 mg poly A RNA from nor-
mal and from AB-variant cells was done as described
elsewhere (Xie et al. 1992b), with use of two radiola-
beled probes consisting of a full-length GM2 activator
cDNA (∼600 bp) and, as a control, a ∼350 bp cDNA
fragment of cytochrome C oxidase complex VI (obtained
from Dr. B. H. Robinson, Hospital for Sick Children).
Total RNA Isolation and RT-PCR
Total RNA was isolated from 150 mm–diameter
plates of confluent cultured fibroblast cells from N1 and
N2 and from the patient, by means of the guanidinium-
thiocyanate method (Chomczynski and Sacchi 1987).
Two primers, 5′-TTGGATCCCACCCTTCCCGATGC-
AG (primer 1680, upstream, 15r16 [counting from
the first “A” of the Activator initiating ATG]) and 5′-
GGATCCGTGGGAGTTTGGCCTTGGC (primer 705,
downstream, 666r648) were designed for reverse tran-
scription and PCR (BamHI sites are underlined). Reverse
transcription was done in a total volume of 100 ml, con-
taining 2 mg total RNA, 0.6 mg primer 705, 0.5 mM
each dNTP, and 200 U MMLV transcriptase (Gibco
BRL). The mixture was incubated at 37C for 1.5 h.
Twenty microliters of these transcription solutions were
directly used for PCR, done in a Robocycler 40 (Stra-
tagene). After a “hot start,” 2.5 U Taq DNA polymerase
(Promega) were added in a 50-ml reaction volume, with
1.25 mM each of primers 705 and 1680, 0.2 mM each
dNTP, and 1.5 mM MgCl2. PCR was done for 35 cycles
each of 2 min at 94C, 30 s at 61C, and 1 min at 72C,
with a final-addition cycle of 2 min at 94C, 30 s at
61C, and 5 min at 72C.
Cloning and Sequencing of Activator cDNA Samples
Two different sizes of cDNA from the RT-PCR prod-
uct, obtained from patient cells after separation, were
observed by means of agarose-gel electrophoresis. These
were purified with the Gene Clean kit (Bio/Can Scien-
tific). One microliter each of the cDNA product from
the patient and 1 ml of fresh RT-PCR product from N1
and N2 were mixed separately with 2 ml PCR 2.1 vector
and 1 ml T4 ligase from the TA cloning kit (Invitrogen)
and then ligated at 14C overnight. One microliter of
the ligation reaction was transformed in INVaF One
Shot Competent Cell (Invitrogen). White clones were
selected and grown in LB media containing 50 mg am-
picillin/ml. Isolation of the plasmid DNA was done with
a Qiagen Mini-Preparation kit.
The DNA sequences of each cDNA were determined
by the dideoxy chain–termination method (see below).
To ensure accuracy, we determined the full-length se-
quences of three clones from each sample, using sense
and antisense strands.
Isolation of Genomic DNA
Confluent fibroblast cells were harvested by scraping
with a rubber policeman, resuspended in 2 ml PBS, and
centrifuged. The cell pellets (from fibroblasts or leuko-
cytes) were resuspended in lysis buffer (100 mM Tris-
Cl [pH 8], 40 mM EDTA [pH 8], 0.2% SDS, and 0.6
mg proteinase K/ml), ground, and incubated at 55C for
10 h. The mixture was extracted with 1 vol phenol/
chloroform, and the DNA was precipitated by addition
of 2 vol 100% ethanol. The DNA pellet was rinsed with
70% ethanol and resuspended in 10 mM Tris (pH 8)
and 1 mM EDTA (pH 8).
Long PCR to Amplify Intron 1 and Intron 2 of GM2A
Two pairs of primers were designed with RIGHT-
PRIMER (BioDisk), for the amplification of intron 1 and
intron 2 of GM2A. The primers for intron 1 were each
composed of 18 nt exonic sequence plus 10 nt, to pro-
duce an XhoI site; that is, 5′-GCGCCTCGAGGACCCA-
CCCTTCCCGATG (primer 2833, upstream, 15r3)
and 5′-GCGCCTCGAGCAGGGGGACACTGGTGCT
(primer 2834, downstream, 228r211) (the XhoI sites
are underlined). The primers for the amplification of
intron 2 were each composed of 32 nt exonic sequence
plus 10 nt, to generate the XhoI site; that is, 5′-GCGC-
CTCGAGTTCCTGGGATAACTGTGATGAAGGGA-
AGGACC (primer 805, upstream, 102r133) and 5′-GC-
GCCTCGAGGGCAGGGCTCCCCAGTAGGAATTA-
ACATGTCA (primer 806, downstream, 376r345).
The rTth extra-long DNA polymerase (rTth XL) was
purchased from Perkin-Elmer. Intron 1 was amplified
with primers 2833 and 2834, by use of the GeneAmp
PCR system 2400 (Perkin-Elmer). An AmpliWax PCR
Gem 100 bead (Perkin-Elmer) was added. PCR was done
in a total volume of 100 ml containing 0.4 mg template,
0.5 mM primers, 4 U rTth XL, 200 mM each dNTP, and
1.1 mM Mg(C2H3O2)2. Denaturation was at 94C for 1
min, followed by 35 cycles each of 15 s at 94C, 30 s
at 60C, and 5 min at 72C; and an extra extension
period of 10 min at 72C.
Intron 2 was amplified with the Advantage KlenTaq
polymerase mix (Clontech), which contained KlenTaq-
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1 DNA polymerase, TaqStart anti-Taq antibody, and mi-
nor Deep Vent DNA polymerase. Intron 2 was amplified
with primers 805 and 806 in a Robocycler 40 (Strata-
gene). PCR was done with a total reaction volume of
50 ml containing 0.4–0.6 mg templates, 0.5 mM primers,
1 ml Advantage KlenTaq polymerase mix, and 200 mM
each dNTP, in a buffer of 40 mM Tricine-KOH (pH 9.2)
containing 15 mM KC2H3O2, 3.5 mM Mg(C2H3O2)2,
and 75 mg BSA/ml. The cycling parameters were dena-
turation at 99C for 35 s, annealing at 67C for 30 s,
and elongation at 68C—first for 9 min during cycles
1–15, then for 11 min during cycles 16–25, and finally
for 13 min during cycles 26–35. Ten microliters each of
the PCR products were mixed with DNA-loading dye
and were analyzed in a 1% agarose gel.
Restriction Analysis of Intron 1 and Intron 2
The PCR products of intron 1 and intron 2 were di-
gested with the following endonucleases: BamHI, SstI,
EcoRI, XbaI, KpnI, HindIII, and XhoI. The digestion
results were analyzed in a 1% agarose gel. Four BamHI-
digestion fragments comprising intron 1 were separated
with QIAEX II gel extraction kit (Qiagen), and each
fragment was digested with the other six endonucleases.
Two SstI-digestion fragments comprising intron 2 were
also separated, and each fragment was digested with the
other six endonucleases.
Determination of the Length of Intron 1 of the
Patient’s GM2A by Long PCR
A fragment containing intron 1 of GM2A was am-
plified from patient fibroblast DNA, by use of primers
2833 and 2834, with rTth XL DNA polymerase (see the
Long PCR to Amplify Intron 1 and Intron 2 of GM2A
subsection, above). Another fragment containing intron
2 of GM2A was also amplified from the patient’s DNA,
by use of primers 805 and 806, with Advantage KlenTaq
polymerase (see the Long PCR to Amplify Intron 1 and
Intron 2 of GM2A subsection, above). Each PCR prod-
uct was digested with BamHI, EcoRI, and BamHI plus
EcoRI and then analyzed in a 1% agarose gel.
Identification and Subcloning of Both Ends of Introns 1
and 2 from Long PCR of Normal Genomic DNA
Restriction analysis showed that two fragments of in-
tron 1 digested by BamHI (0.6 kb and 1.2 kb) were the
5′ and 3′ ends of intron 1 (which contains terminal XhoI
sites). These two fragments were digested independently
with XhoI and were purified with use of the QIAEX II
gel extraction kit. One hundred nanograms of each frag-
ment was then ligated into the BamHI/ XhoI sites of 30
ng pBluescript vector (Stratagene), with T4 ligase (Boer-
hinger). The ligation products were transformed with
XL-Blue MRF competent cell (Stratagene). White clones
were selected and grown in LB media containing 50mg
ampicillin/ml. Isolation of the plasmid DNA was done
with the Qiagen Mini-Preparation kit. Four-kilobase and
2.9-kb fragments of intron 2 digested with SstI were also
subcloned into the SstI/XhoI site of the same vector and
were analyzed by similar methods.
Nucleotide Sequencing on the Normal 5′ and 3′ Ends
of Introns 1 and 2
The nucleotide sequences of the preceding inserts were
determined by the dideoxy-chain–termination method
(Sanger et al. 1977). Plasmid DNA products (1.5 mg)
containing each end of the introns were mixed with 30
ng each of T7 or T3 primers (Stratagene), a[35S]-dATP
(Amersham), and other components of the Sequenase
kit as recommended by the manufacturer (Pharmacia).
To confirm the sequences of the introns, we sequenced
both antisense and sense strands from PCR products
obtained from five different normal genomic DNA
samples.
Designing an Efficient PCR Method to Amplify the
Exons and Exon/Intron Junctions of GM2A
On the basis of the nucleotide sequences obtained
from the 5′ and 3′ ends of the introns (GenBank), four
pairs of primers were designed (table 1) with RIGHT-
PRIMER (BioDisk). Fragments made up of exons and
their intronic flanking regions were amplified with each
pair of primers (table 1) by use of a GeneAmp PCR
System 2400 (Perkin-Elmer). PCR was done in a total
volume of 100 ml containing 0.6 mg genomic DNA, 0.5
mM primers, 0.2 mM each dNTP, 2.5 mM MgCl2, and
2.5 U Taq-Gold DNA polymerase (Perkin-Elmer). The
cycling parameters used were as follows: 10 min at 94C
for denaturation; 43 cycles each of 30 s at 94C, 30 s
at 54C, and 30 s at 72C; and then 10 min at 72C for
elongation. With these conditions, PCR amplification of
exon 3 and its flanking region produced some nonspe-
cific DNA. Although these nonspecific bands did not
interfere with the isolation of the target fragment, it was
determined that they could be removed by lowering the
concentration of MgCl2 to 2.0 mM. On the basis of
exonic and intronic sequences obtained from this and a
previous study (Xie et al. 1991), each of the PCR frag-
ments—E1, E2, E3, and E4—was designed to contain a
unique restriction site, XbaI, SstI, PstI, and EcoRI, re-
spectively (table 1). These restriction digestion sites can
be used as controls to confirm the identity of each am-
plified fragment.
PCR of Genomic DNA Fragments from Patient and
Controls
Exon 1, exon 2, and their flanking regions in GM2A
were amplified from the genomic DNA of the patient
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Table 1
Sequence of the Primers Used to Amplify Exons and Exon/Intron Junctions of GM2A
EXON AND PRIMERS
(22 nt) 5′ LOCATIONa
MELTING
TEMPERATURE
(C)
SIZE
(bp)
VERIFICATION DIGEST
Enzyme
Fragment
(bp)
E1:
GGAAGGCATTTAAAGGACCTCT E1 (69) 58.1 426 XbaI 246180
AAGGCTGTCTGCATTTTCACTC IVS 1 (256) 60.0
E2:
CCCAGGTTCATAGGTATGGAGT IVS1 (149) 56.2 528 SstI 76452
GCTGGCGCTGACATCAGAGATT IVS2 (218) 56.2
E3:
GATTATTAATGTCTGCCATGGG IVS2 (220) 54.4 716 PstI 484232
GCTAGGATTGCAGCCATGAACT IVS3 (313) 58.1
E4:
CATGTCTCTGGATTTGTAAGCC IVS3 (290) 56.2 665 EcoRI 312352
GGCTATCAAGAACTGTCCAACT E4 (802) 56.2
NOTE.—Part of the 3′ UTR is excluded from the data.
a Nucleotide numbering in exonic sequences is done from the “A” of the first ATG as nt 1; nucleotides in intronic
sequences are numbered from the first nucleotide of the 5′ end of the intron (plus number) or the last nucleotide of 3′
end of the intron (minus number).
Figure 1 Western blot analysis, done with a primary rabbit anti-
Activator IgG, of fibroblast lysate (either 50 or 100 mg total protein)
from N1, N2, and the patient.
and N1 and N2 with use of the first and second pairs
of primers in table 1, as described in the previous sec-
tions. Each PCR product was purified with the QIAGEN
PCR purification kit and directly sequenced.
Direct Sequence of PCR Fragments
To examine the nucleotide sequences at both ends of
introns 1 and 2, we performed direct sequencing of the
above PCR fragments, using the Thermosequenase ra-
diolabeled terminator cycle sequencing kit (Amersham).
The reactions were done in a Robocycler 40 (Straga-
gene), with 2 min at 94C for denaturation and 25 cycles
each of 30 s at 94C, 30 s at 55C, and 1 min at 72C.
Detection of the Exon 2 Deleted Activator mRNA in
Normal Cells
DNA sequences from GM2A showed that only a sin-
gle HinfI site exists in the cDNA encoding the Activator,
and it resides in exon 2. Therefore, the full-length cDNA
can be cleaved by HinfI, whereas any cDNA species
lacking exon 2 will remain intact after digestion. Five
microliters each of RT-PCR products from N1 and from
the patient sample were digested with HinfI. Two
“nested” primers, ATCGCCCTGGGCTTGCTT (primer
1438, upstream, 31r48) and ACAAAACAGAGGAA-
AAGG (primer 1968, downstream 642r625), were used
for a second round of PCR. Nested PCR amplification
was done with 1 ml/50 ml digested RT-PCR products or
with an equal amount of undigested RT-PCR products,
with 0.2 mM each of primers, 1.0 mM MgCl2, and 0.2
mM each dNTP. The cycling parameters were 10 min
at 94C for denaturation; 35 cycles each of 30 s at 94C,
30 s at 61C, and 30 s at 72C; and then a final 10 min
at 72C for elongation. Ten nanograms of either the
wild-type or of the exon 2–deleted cloned cDNA, as well
as an H2O sample, were included as controls for the
nested PCR amplification.
Results
The initial diagnosis of the acute AB-variant form of
GM2 gangliosidosis given the patient was done on the
basis of his clinical presentation coupled with the pres-
ence of normal levels of both Hex A and B in his leu-
kocytes and plasma (see the Case Report subsection,
above). Because the four previously described GM2A
mutations causing disease result in undetectable levels
of Activator cross-reacting material (CRM), we first an-
alyzed the lysate from the patient’s fibroblasts by using
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Figure 2 RT-PCR of total RNA from N1, N2, and the patient.
Arrows indicate the normal-sized product (691 bp), the unexpected
smaller product (529 bp) found only in the patient’s cDNA, and, in
lane M containing lDNA/ HindIII markers, the sizes of the surround-
ing markers.
Figure 3 Partial nucleotide sequence of a cDNA fragment from
a normal control and the patient. The arrows indicate the single
G160rT transversion found.
western blotting. Whereas lysate from two normal con-
trol cell lines produced easily detectable immunoreactive
bands corresponding to the expected molecular weight
of 22,000, a similar band was not detectable in lysate
samples from the patient’s cells containing similar levels
of total protein (fig. 1). This observation confirmed the
patient’s diagnosis.
We next examined the level of Activator mRNA from
poly A RNA isolated from patient and normal cells.
No Activator mRNA could be detected in the patient’s
sample (data not shown). To determine whether any
RNA was transcribed from either of the patient’sGM2A
alleles, we performed RT-PCR. Although this procedure
resulted in the expected single 691-bp band in samples
from two normal cell lines (fig. 2, lanes N1 and N2),
two bands were amplified from the patient’s sample,
corresponding to 691 and 529 bp (fig. 2, lane P). How-
ever, the amount of the smaller cDNA was much less
than the larger, normal-sized cDNA.
The cDNAs from N1 and N2 and the two different-
sized cDNAs from the patient’s cells (fig. 2) were cloned
and their sequences were determined. The sequence of
the cDNA from N1 was consistent with the previously
published wild-type sequence. However, the cDNA from
N2 contained a single G175rA transition, which would
encode a Val59Ile substitution in the Activator protein.
This substitution was also found in DNA samples from
several other normal individuals (data not shown); thus,
it must represent a common neutral polymorphism.
More significantly, in the larger cDNA from the patient,
a G160rT transversion in exon 2 was found (fig. 3),
which converts the codon for Glu54 to a STOP codon.
The smaller cDNA was also sequenced and determined
to have an in-frame deletion of the same exon 2 (fig. 4).
The complete sequences of both cDNAs were ascertained
and determined to have no other changes from the wild
type. Identical data were obtained from at least one other
clone of each cDNA, from different RT-PCR products
(data not shown).
To determine the mechanism responsible for the
smaller cDNA found in the patient’s RT-PCR product,
we first completed the characterization of the normal
GM2A structure. The size of intron 1 and 2 was deter-
mined by long PCR of genomic DNA from a normal
individual. The initial primers used to amplify both in-
trons were located on exons, and these exonic sequences
allowed us to orient the cDNA fragments in GM2A. The
PCR product containing the 3′ end of exon 1, all of
intron 1, and the 5′ end of exon 2 was ∼6.7 kb in length
(fig. 5, lane I1), indicating that intron 1 is ∼6.45 kb long.
The PCR product containing the 3′ end of exon 2, all
of intron 2, and the 5′ end of exon 3 was ∼6.9 kb (fig.
5, lane I2), indicating that the length of intron 2 is ∼6.60
kb. These long-PCR analyses were also done on DNA
samples from the patient’s cells and produced identical
results (data not shown). Restriction-digestion patterns
of the two long-PCR products from the patient’s DNA
were also identical to those from normal samples (data
not shown).
By combining our new data with previously deter-
mined sequence data, we were able to generate a re-
striction map of the entire gene (fig. 6A). Also, by cloning
and sequencing each intron-exon–junction fragment, we
were able to design four pairs of PCR primers (fig. 6B;
table 1) that can amplify the gene with common PCR
conditions (see the Patient and Methods section, above).
In addition, each PCR fragment was designed to contain
a unique restriction site that allows for an easy confir-
mation of its identity (fig. 7, table 1).
Using our newly designed primer sets “E1” and “E2”
(table 1) to amplify the patient’s DNA, we obtained
single bands of the expected sizes, 426 and 528 bp, re-
spectively (data not shown). Direct sequencing of these
fragments showed that the patient was either homozy-
gous for the nonsense mutation G160rT or heterozy-
gous for that mutation and for a large GM2A-deletion
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Figure 4 Partial-nucleotide sequence of the smaller cDNA RT-
PCR product from patient samples, and cDNA fragments from normal
controls.
Figure 5 Determination of the length of intron 1 (∼6.45 kb) and
intron 2 (∼6.60 kb) of GM2A. Intron-containing fragments were am-
plified by long PCR with use of exonic primers. Each fragment con-
tained ∼150 bp exonic sequence at each end. Size markers (“M”) are
also shown.
allele (fig. 8). All other sequences, including those at the
exon 1/ intron 1, intron 1/exon 2, and exon 2/intron 2
junctions, were normal (data not shown). Thus, neither
these nor any of the above data explain the presence of
the exon 2–deleted cDNA species (DE2) seen in the pa-
tient’s—but not in the normal controls’—RT-PCR prod-
ucts (fig. 2).
Because northern blotting was unable to detect any
Activator mRNA (either normal-sized or DE2; data not
shown) in the patient’s cells, we believed it was possible
that a similarly low level of the smaller DE2 might also
be present in normal RT-PCR samples (i.e., a naturally
occurring, alternatively spliced form of mRNA), but, be-
cause of the relatively high level of normal Activator
mRNA in the controls, DE2 was not detectable by RT-
PCR. To test this theory, we developed a nested PCR
procedure specifically for use on the DE2 product. Be-
cause only one HinfI site exists in normal Activator
cDNA and since it is located in exon 2, digestion of the
normal RT-PCR fragment with this enzyme should pre-
clude its amplification, while at the same time allowing
amplification of DE2, with use of nested primers 1438
and 1968 (see the Detection of the Exon 2 Deleted Ac-
tivator mRNA in Normal Cells subsection, above) for
a second round of PCR. Without digestion by HinfI, the
second-round PCR product of the normal sample pre-
dominantly contained the full-length product, but some
of the small DE2 became visible (fig. 9, lane 3), although
still apparently less than can be seen in the patient’s
sample (fig. 9, lane 4). However, after the digestion of
both the patient’s and the normal control’s RT-PCR
products with HinfI, the second-round nested PCRs pro-
duced predominantly the DE2 cDNA fragment in about
equal amounts (fig. 9, lanes 5 and 6). A small amount
of the full-length fragment is also detectable, to reflect
the fact that restriction digestions are not 100% efficient
(Valentine and Heflich 1997). Significantly, none of the
DE2 product was detected in the PCR products from
cloned normal cDNA (fig. 9, lane 1), indicating that the
DE2 cDNA was a small, undetectable component in the
first-round normal RT-PCR sample (fig. 2, lanes N1 and
N2), and its presence in the second round of PCR (fig.
9, lanes 3 and 5) was not caused by contamination. The
lack of contamination is also supported by the negative
H2O control (fig. 9, lane 7).
Discussion
The Activator is a small monomeric protein of 193
amino acids, and the first 23 residues are predicted to
serve as a signal peptide, which is removed cotransla-
tionally. In the lysosome, further processing of the N
terminus results in a mature chain of 162 residues (re-
viewed by Mahuran 1998). The deficiency of the Acti-
vator results in the AB-variant form of GM2 ganglios-
idosis, which is a very rare disease (Gravel et al. 1995;
Sandhoff et al. 1995). Only four disease-associated mu-
tations have been described: DAAG264 (DLys88), DA410
(33 new amino acids, with a loss of 24; Schepers et al.
1996), and T412rC (Cys138Arg) (Schro¨der et al. 1991;
Xie et al. 1992b) in exon 3; and G506rC (Arg169Pro)
(Schro¨der et al. 1993) in exon 4. These were all presumed
to be present in the homozygous form in the four re-
spective patients. Whereas none of these mutations result
in detectable Activator CRM in patient cells, all of them
have been reported to result in normal steady-state levels
of Activator mRNA. Cells from the new AB-variant pa-
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Figure 6 A, Restriction map of GM2A; B BamHI, E EcoRI,
S  SstI, X  XbaI, K  KpnI, and H  HindIII. No XhoI sites were
present in intron 1 or 2. The numbers with each restriction site indicate
the number of times it has appeared, reading from 5′ to 3′ in the gene
structure. Intron lengths are given in brackets. The unblackened boxes
refer to exons, and the blackened boxes refer to 5′ and 3′ UTRs of the
cDNA. B, Sequence of the exons and exon/intron junctions of GM2A;
intronic sequences are given in lowercase, the encoding exonic se-
quences in bold uppercase, and the untranslated exonic sequences in
regular uppercase. The translation initiation (exon 1) and termination
(exon 4) sites are wavy-underlined. The forward and reverse primers
for amplification of the 4 exons and their flanking regions are single
underlined and double underlined, respectively. The number followed
by an arrow and either an “F” (forward) or “R” (reverse) in brackets
above each primer indicates the exon being amplified and also the
primer’s direction (see table 1). The unique restriction site in each
fragment, used to confirm its identity, is dotted-underlined. Three re-
ported exonic polymorphisms are indicated with an asterisk (*). The
two new polymorphisms identified during this study, G175A and IVS1
a-92t, and are indicated with a pound sign (#). We also report the
correction of previously published sequences at IVS1–12 and IVS1–15
(Klima et al. 1991), which are indicated by a caret (^).
tient we report here show no detectable steady-state
mRNA or any CRM, by northern (data not shown) or
western blotting (fig. 1), respectively. Only when we per-
formed RT-PCR could Activator mRNA of normal size
be detected in the patient’s cells, but we also observed
a smaller cDNA species present at an even lower level
(fig. 2). Nucleotide sequencing of the cDNAs uncovered
a nonsense mutation in exon 2 at the codon for Glu54
(encoding the loss of 140 residues) in the normal size
(fig. 3), and an in-frame deletion of exon 2 in the smaller
cDNA, DE2 (fig. 4), which retains the original open read-
ing frame. Direct sequencing of genomic DNA indicated
that the patient’s intron/exon junctions and flanking se-
quences of his GM2A gene were normal (data not
shown) and that he appeared to be homozygous for the
nonsense mutation (fig. 8). These data eliminated the
possibility that the low level of the smaller DE2, detected
by RT-PCR in the patient’s cells, was a product of ab-
normal splicing from a second mutant allele but cannot
totally exclude the possible presence of a second very
large GM2A deletion allele (i.e., the patient is
hemizygous).
Premature STOP codons can be generated directly by
a nonsense point mutation or indirectly by a frame-shift
mutation. The latter can be generated by abnormal
mRNA splicing, deletions, or insertions. There are nu-
merous cases of these types of mutations causing GM2
gangliosidosis (Gravel et al. 1995; Mahuran, in press).
Of those in HEXA or HEXB, where steady-state mRNA
levels have been reported, only 1 of 13 have not been
associated with a dramatically reduced amount of tran-
script (Gravel et al. 1995; Mahuran, in press). This lone
exception also produces the most–C-terminal STOP co-
don, DC1510, in exon 13 of 14 in HEXA and results
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Figure 7 PCR fragments containing exons E1–E4 and their
flanking intronic sequences, amplified with the primers in table 1. Each
fragment is shown intact undigested (UD) or digested with its unique
restriction site. X  XbaI, S  SstI, P  PstI, and E  EcoRI (table
1). Size markers (M; 100 bp) are also shown.
Figure 8 Direct nucleotide sequence of a PCR fragment (fig. 6B
and fig. 7 E2) of genomic DNA from the patient and a normal control.
Arrows indicate the homozygous G160T mutation in the patient’s
DNA.
in the loss of only 22 residues (Zokaeem et al. 1987).
In contrast to the effect of early STOP codons on steady-
state levels of mutant mRNA, the four in-frame deletions
or insertion mutations that have been characterized in
HEXA and HEXB all produce normal levels of mutant
mRNA (Mahuran, in press). An example of this type of
mutation is the major HEXA mutation among Japanese
Tay-Sachs patients, in which a “g1t” substitution in
intron 5 results in the in-frame deletion of exon 6 (Ta-
naka et al. 1993). Identical observations have been made
for similar mutations in other genes (Maquat 1996).
In light of these examples, we believe that it is not
surprising that the premature STOP we report in exon
2 at codon 54 results in no detectable Activator mRNA,
by northern blotting, in the patient’s cells, whereas a
previously reported STOP in exon 3 at codon 170 does
(Schepers et al. 1996). However, the presence of an even
lower steady-state level of the smaller DE2 product de-
tected by RT-PCR in the patient’s cells, but not in normal
cells, remained to be explained. If this was caused by a
second unidentified deletion allele, the deletion would
have to encompass all of exon 2 and either 1149 bp of
the 3′ end of IVS1 or 1218 bp of the 5′ end of IVS2;
otherwise, the deletion would have been detected by long
PCR done with our exonic primers (see the Long PCR
to Amplify Intron 1 and Intron 2 of GM2A subsection,
above) or by conventional PCR done with the intronic
primers we subsequently designed to amplify exon 2 and
its flanking sequences (see table 1, exon E2). It is unlikely
that such a deletion would be able to transcribe an RNA
product that was missing only exon 2. Furthermore, be-
cause no early STOP codon is present in the DE2 RNA,
its stability should be similar to that of the wild-type
transcription product (Maquat 1996). Thus, the very
low level of DE2 RNA strongly indicates that it is not
transcribed by a second unidentified deletion allele but
is an alternatively spliced form of RNA transcribed from
the homozygous or hemizygous Glu54STOP GM2A al-
lele(s) of the patient (our data do not eliminate the pos-
sible presence of a second, very large deletion allele that
does not transcribe Activator RNA detectable by RT-
PCR).
Our present data do not prove conclusively that the
patient is homozygous for the nonsense mutation, and
his pedigree revealed no consanguinity. However, two
observations indicate that it is still likely that both of
his GM2A alleles contain the Glu54STOP mutation.
First, the AB-variant form of GM2 gangliosidosis is a
very rare disease, and all four of the previously char-
acterized patients were also likely homozygous for their
distinct mutations (hemizygosity also could not be ruled
out in these cases). Second, the patient’s family belongs
to a deme, the Hmong, a small Laotian hill tribe, and
it is unlikely that two GM2A mutant alleles would exist
in such a small population. For example, the HEXB
mutations responsible for Sandhoff disease (also a rare
disease, but still much more common than the AB-var-
iant) in an Argentinean deme have been characterized.
It was concluded that there was only a single novel high-
frequency splice-site mutation present in this population
(Kleiman et al. 1994).
There has been a great deal of previously reported
data concluding that shortened reading frames (i.e., early
STOP codons), can lead not only to mRNA instability,
but also to the in-frame skipping of the constitutive exon
in which the mutation is found (Dietz et al. 1993; Dietz
and Kendzior 1994; Ronce et al. 1997; Mazoyer et al.
1998). There remains a controversy as to whether this
is caused by a mechanism in the nucleus that can sense
the lack of an open reading frame and effect normal
splicing (reviewed by Maquat 1996). All but the data
we present in figure 9 would appear to support the pres-
ence of such a mechanism.
The procedure we used to demonstrate the presence
of similar amounts of DE2 in both normal and mutant
cells (see fig. 9) was based on an experiment reported
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Figure 9 Nested PCR–amplified RT-PCR product from the pa-
tient and a normal control. “DE2” and “WT” refer to the cDNAs
missing or containing exon 2, respectively. Undigested RT-PCR prod-
uct (UD) or the RT-PCR products digested with HinfI prior to the
second nested PCR procedure, HinfI, are indicated. Cloned WT and
DE2 cDNA, as well as a H2O control sample (C) were also subjected
to the nested PCR procedure. Size markers (M) are identified with
arrows.
by Valentine and Heflich (1997). They examined a ho-
mozygous nonsense mutation associated with exon skip-
ping in hprt mRNA of Chinese hamster ovary cells and
concluded that the apparent increase in exon skipping
was an RT-PCR artifact. This artifact was caused by the
instability, and thus very low steady-state levels, of the
normal-sized RNA containing the nonsense mutation,
coupled with the normal stability of the smaller DE-
RNA, in which the nonsense mutation had been deleted
and the reading frame had been restored. This small DE-
RNA was found to be produced constitutively at very
low levels in normal as well as in mutant cells. However,
it could be amplified to a level of detectability in normal
cells only after the removal of the full-length wild-type
RT-PCR–generated cDNA by digestion with a specific
restriction enzyme, followed by a second nested PCR.
Thus, our data presented in figures 2 and 9 are in full
agreement with the conclusion made by Valentine and
Heflich and do not support the presence of a nuclear
mechanism that can sense the frame of precursor mRNA
and affect final splicing events.
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